Tuesday, June 29, 2010 (Last Updated: 06/30/2010)
TUESDAY, June 29 (HealthDay News) -- In men who undergo radical prostatectomy for prostate cancer, those who take statins have a decreased risk of biochemical recurrence, according to research published online June 28 in Cancer.
Robert J. Hamilton, M.D., of Duke University in Durham, N.C., and colleagues assembled data from the Shared Equal Access Regional Cancer Hospital Database on 1,319 men who underwent radical prostatectomy. The cohort included 236 men who were taking statins at the time of their surgery. The statin users were followed for a mean of 24 months and nonusers were followed for a mean 38 months.
The researchers found that patients taking statins had a 30 percent lower overall risk of prostate-specific antigen recurrence than those not taking statins. The reduction in risk was dose-dependent, with the recurrence risk lowered as statin dose increased. For example, the equivalent of simvastatin at a dose of 20 mg was associated with a 43 percent reduced risk of recurrence, while subjects taking the equivalent of a greater than 20 mg dose of simvastatin had a 50 percent reduced risk.
"Given that statins have proven efficacy in preventing cardiovascular mortality, if it is definitively proven that statins reduce recurrence after surgery, then the potential influence statins could have on overall and disease-specific mortality is substantial," the authors write.
Hematology & Oncology
Copyright © 2010 HealthDay. All rights reserved.